Ivermectin is safe for humans when taken at the doses approved for its established uses, which center on parasitic infections and certain skin conditions. Billions of doses have been distributed worldwide since the 1980s, and at standard dosing the side-effect rate in large treatment campaigns sits around one to two percent, mostly headaches, dizziness, and mild stomach upset. The safety picture gets more complicated, though, when doses climb beyond approved levels, when certain co-infections are present, or when people take formulations meant for livestock.
What Ivermectin Is Approved For
Ivermectin was discovered in the 1970s, derived from a soil bacterium, and its development earned a share of the 2015 Nobel Prize in Physiology or Medicine for what the Nobel Committee called discoveries that “revolutionized therapy for patients suffering from devastating parasitic diseases.”1PubMed Central. Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19 The drug works by targeting a type of chloride channel found in the nerve and muscle cells of parasites and insects, essentially paralyzing them.2Trends in Parasitology. Ivermectin: The Anthelmintic and Insecticide Humans lack that particular channel type in their peripheral nervous system, which is a big part of why the drug can kill worms and insects at doses that leave people largely unharmed.
In humans, oral ivermectin is approved for treating several parasitic conditions. For river blindness (onchocerciasis), a single oral dose can reduce the load of larval worms in the skin by roughly 90 percent within a few days and up to about 98 percent over the following weeks.3European Journal of Medicinal Chemistry. Antiparasitic activity of ivermectin: Four decades of research into a “wonder drug” – Section: 3.1. In humans For threadworm infections (strongyloidiasis), the standard course in the United States is oral ivermectin at 200 micrograms per kilogram of body weight for two consecutive days, sometimes repeated two weeks later.3European Journal of Medicinal Chemistry. Antiparasitic activity of ivermectin: Four decades of research into a “wonder drug” – Section: 3.1. In humans It is also used for scabies and head lice. Both topical and oral forms show high effectiveness against head lice, with cure rates reaching close to 100 percent after a second treatment when needed.4PubMed. Assessment of topical versus oral ivermectin as a treatment for head lice
A topical formulation, ivermectin 1% cream, is approved for the inflammatory bumps of rosacea. Trials comparing it to a commonly used alternative found that the ivermectin cream produced better results in reducing lesion counts and redness, with an acceptable safety profile.5PubMed Central. New developments in the treatment of rosacea – role of once-daily ivermectin cream
Why It Is Generally Safe at Approved Doses
The reason ivermectin can kill parasites while sparing the human host comes down to a biological gatekeeper called P-glycoprotein. This protein sits on the surface of the cells that line blood vessels in the brain and actively pumps ivermectin back out before it can accumulate in the central nervous system.6PubMed Central. Ivermectin: does P-glycoprotein play a role in neurotoxicity? At the concentrations reached by standard oral doses, P-glycoprotein handles the job easily, keeping brain levels of the drug negligible. Animal research confirms this dramatically: mice and dogs that lack a functional gene for P-glycoprotein accumulate ivermectin in the brain at dangerous levels, developing severe neurological symptoms and sometimes dying.7PubMed. Brain penetration of ivermectin and selamectin in mdr1a,b P-glycoprotein- and bcrp- deficient knockout mice In humans with a normal, functioning blood-brain barrier, the drug stays out of the brain at approved doses, and side effects remain mild.
Large-scale mass drug administration campaigns provide the strongest evidence of population-level safety. In a cluster-randomized trial in Ethiopia involving thousands of participants, adverse events were reported by about 1.2 percent of individuals, with headache, gastrointestinal disturbance, and dizziness as the most common complaints. No serious adverse events occurred in either treatment arm.8eClinicalMedicine. Safety of integrated mass drug administration of azithromycin, albendazole and ivermectin versus standard treatment regimens: a cluster-randomised trial in Ethiopia A similar trial in Burkina Faso, which used repeated ivermectin dosing to study malaria reduction, found adverse events in about 2 percent of participants, with the ones classified as possibly or probably drug-related all being mild or moderate in severity, such as vomiting, itching, or mild swelling, and all resolving on their own or with standard care.9The Lancet. Effect of frequently repeated ivermectin mass treatments on malaria incidence in Burkina Faso (RIMDAMAL): a cluster-randomised trial
When Ivermectin Becomes Dangerous
The safety profile changes sharply in certain situations. The most well-documented risk involves people who carry a heavy burden of a particular parasitic worm called Loa loa, found in parts of central Africa. When ivermectin rapidly kills enormous numbers of these microfilariae circulating in the blood, the dying parasites can trigger severe inflammation in the brain. Patients with very high Loa loa loads, above about 50,000 microfilariae per milliliter of blood, face an extremely elevated risk of encephalopathy, including coma.10The Lancet. Ivermectin does not cause severe encephalopathy Several cases of coma have been documented in patients treated for river blindness who also had heavy Loa loa infections.11PubMed. Three probable cases of Loa loa encephalopathy following ivermectin treatment for onchocerciasis
A systematic pharmacovigilance study examining serious suspected adverse drug reactions found that compared to similar antiparasitic drugs, ivermectin was associated with higher reporting rates of skin reactions, encephalopathies, and confusion. These encephalopathy reports were not limited to areas where Loa loa is endemic; they occurred in other parts of the world as well.12PLOS Neglected Tropical Diseases. Serious adverse reactions associated with ivermectin: A systematic pharmacovigilance study in sub-Saharan Africa and in the rest of the World This finding is consistent with the broader principle that anything impairing the P-glycoprotein efflux system, whether genetics, drug interactions, or sheer dose overload, can open the door to neurotoxicity.
How Your Body Processes Ivermectin and What Can Go Wrong
Ivermectin is broken down in the liver almost entirely by a single enzyme, CYP3A4.13PubMed. Identification of cytochrome P4503A4 as the major enzyme responsible for the metabolism of ivermectin by human liver microsomes Studies of human liver tissue confirmed that a specific inhibitor of CYP3A4 was by far the most potent at blocking ivermectin metabolism, and an antibody targeting the same enzyme shut down about 90 percent of the drug’s breakdown. The main metabolites produced are a demethylated form and a hydroxylated form.14PubMed Central. Identification of the metabolites of ivermectin in humans
This near-total dependence on one enzyme creates a meaningful drug interaction risk. If you are taking another medication that strongly inhibits CYP3A4 — certain antifungals, some antibiotics, and several HIV drugs fall into this category — ivermectin can build up in your bloodstream beyond expected levels. Similarly, because P-glycoprotein also actively pumps ivermectin out of cells, drugs that inhibit P-glycoprotein transport could raise plasma concentrations and increase the risk of toxicity.15PubMed Central. Metabolism and interactions of Ivermectin with human cytochrome P450 enzymes and drug transporters, possible adverse and toxic effects In practice, this means you should tell your prescriber about all other medications before taking ivermectin, especially anything that might affect either CYP3A4 or P-glycoprotein.
Overdoses and Veterinary Formulations
Ivermectin intended for livestock comes in vastly higher concentrations than the human tablets, because horses and cattle weigh many times what a person does. During the COVID-19 pandemic, poison control centers saw a spike in calls related to ivermectin toxicity. An analysis of these cases found that the most common clinical effects were neurological symptoms, gastrointestinal complaints, and musculoskeletal problems. People who had taken veterinary products used higher doses and were more likely to develop altered mental status than those taking the standard human prescription tablets.16PubMed. Characteristics of ivermectin toxicity in patients taking veterinary and human formulations for the prevention and treatment of COVID-19
The risk is straightforward: veterinary formulations are not designed for human dosing, and the concentration differences make accidental overdose easy. Regulatory agencies have warned against purchasing ivermectin from unverified online sources, in part because counterfeit or substandard products can bypass the quality controls that make approved human tablets predictable and safe.17PubMed Central. TGA warns against buying ivermectin online from unverified sources
Individual Vulnerability and Genetics
Given how central P-glycoprotein is to keeping ivermectin out of the brain, an obvious question is whether genetic variations in the gene encoding it (called ABCB1 or MDR1) could make some people more vulnerable to neurotoxicity. Researchers have identified numerous single-nucleotide variations in ABCB1 across different populations, and their frequencies vary by ethnicity.18PubMed. Potential impact of ABCB1 (p-glycoprotein) polymorphisms on avermectin toxicity in humans Reassuringly, studies in living humans have found that the two most common ABCB1 gene combinations both maintain full blood-brain barrier function.18PubMed. Potential impact of ABCB1 (p-glycoprotein) polymorphisms on avermectin toxicity in humans Still, rarer variants or combinations have not been fully ruled out, and the broader principle holds: any factor that weakens this protective pump, whether genetic, pharmacological, or pathological, is the central determinant of whether ivermectin becomes neurotoxic.19PubMed Central. Ivermectin Toxicity in Humans and Animals: Clinical Spectrum, Mechanisms, and Management
Pregnancy and Children
Ivermectin is generally not recommended during pregnancy because safety data remain thin. A systematic review and meta-analysis looked at cases where pregnant women were inadvertently exposed to the drug, mostly through mass treatment campaigns. The review found no reports of neonatal deaths, maternal illness, preterm births, or low birth weight. Whether ivermectin slightly raises the risk of spontaneous abortions, stillbirths, or birth defects remained unclear from the available data, with very low certainty of evidence in both directions.20The Lancet Global Health. Safety of ivermectin following inadvertent exposure in pregnancy: a systematic review and meta-analysis In short, there is no clear signal of harm, but there also is not enough evidence to declare it safe. Most treatment programs exclude pregnant women from mass dosing as a precaution. Children weighing less than 15 kilograms are likewise typically excluded because dosing data in very young children are limited.
The COVID-19 Chapter
The single most contentious aspect of ivermectin’s recent history is its proposed use against COVID-19. Early in the pandemic, a laboratory study showed that ivermectin could inhibit SARS-CoV-2 replication in cell cultures. The problem was that the concentration required to achieve that effect was estimated at roughly ten-fold higher than the maximum approved human dose, raising serious safety concerns about whether antiviral concentrations could ever be reached safely in a living person.21PubMed Central. Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19
Multiple large, well-designed randomized clinical trials followed, and they consistently found no meaningful benefit. The TOGETHER trial in Brazil, one of the largest, found that ivermectin-treated patients had a primary outcome event rate of about 15 percent compared to about 16 percent for placebo, a difference that was not statistically significant.22PubMed. Effect of Early Treatment with Ivermectin among Patients with Covid-19 The ACTIV-6 trial in the United States found that at a standard dose of 400 micrograms per kilogram, ivermectin did not significantly shorten the time to recovery, with a median of 12 days in the ivermectin group versus 13 days for placebo, falling below the pre-specified threshold for benefit. Adverse events were uncommon and similar between both groups.23JAMA. Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial
Some advocates argued that higher doses or longer courses might work where standard doses had failed. But even at 600 micrograms per kilogram daily for six days, a dose triple the standard antiparasitic amount, no benefit was found. A Cochrane meta-analysis pooling eleven eligible trials reached the same conclusion, and three additional large trials published afterward confirmed it. At the doses and durations tested, ivermectin did not appear to be associated with serious adverse effects, but it also did not help.24JAMA. At a Higher Dose and Longer Duration, Ivermectin Still Not Effective Against COVID-19 The evidence here is about as definitive as clinical medicine gets: ivermectin does not treat or prevent COVID-19.
Parasite Resistance to Ivermectin
A less publicized but consequential concern is whether widespread use of ivermectin could breed resistance in the parasites it was designed to fight. There is evidence this is already happening. In a laboratory model using a species of threadworm, repeated subtherapeutic doses of ivermectin produced measurable drug resistance by the fourth generation, with the resistant worms showing increased activity of molecular pumps that eject the drug before it can do its job.25PubMed Central. Repeated Ivermectin Treatment Induces Ivermectin Resistance in Strongyloides ratti by Upregulating the Expression of ATP-Binding Cassette Transporter Genes
In the field, studies of the river blindness worm Onchocerca volvulus have found genetic shifts after years of ivermectin treatment. After multiple rounds of dosing, the proportion of worms carrying a particular gene variant associated with reduced drug sensitivity increased significantly, with the effect more pronounced when treatments were given every three months rather than annually.26PLoS Neglected Tropical Diseases. Genetic Selection of Low Fertile Onchocerca volvulus by Ivermectin Treatment Treatment frequency, rather than dose size, drove the genetic shift. This matters because ivermectin remains one of very few tools available for controlling river blindness in much of sub-Saharan Africa, and resistance could undermine mass treatment programs that protect hundreds of millions of people. Using ivermectin for conditions it does not actually treat, as happened widely during the pandemic, is exactly the kind of unnecessary pressure that accelerates resistance in the parasites where the drug genuinely saves lives.
Practical Considerations for Safe Use
If your doctor prescribes ivermectin for a legitimate parasitic infection or an approved dermatological condition, the safety record at standard doses is strong. The drug has been used in mass campaigns covering entire communities for decades with a consistently low rate of mild side effects. A few practical points are worth keeping in mind:
- Take it as prescribed: The standard oral dose for most parasitic infections is 150 to 200 micrograms per kilogram, given as a single dose or over a couple of days depending on the condition. Exceeding this without medical supervision increases the risk of neurological effects.
- Disclose all medications: Because ivermectin depends so heavily on CYP3A4 for metabolism and P-glycoprotein for brain protection, any drug that inhibits either of those pathways can raise ivermectin levels in your body unpredictably.
- Avoid veterinary products: These are formulated for animals weighing hundreds of kilograms. Measuring a human dose from a horse paste tube is guesswork with real consequences.
- Travel and co-infections matter: If you have traveled to or live in areas where Loa loa is present, your doctor should check for that infection before prescribing ivermectin, because a heavy parasite load can turn a safe drug into a dangerous one.
Ivermectin remains one of the most important antiparasitic drugs ever developed, and its safety at approved doses in appropriate patients is well established by decades of evidence. The problems arise when people take doses far beyond what has been studied, use formulations not meant for humans, or apply it to diseases where it has been shown not to work. A drug’s safety is never a property of the molecule alone; it is a function of how the drug is used.